A mathematical model of bimodal epigenetic control of MIR-193a in ovarian cancer stem cells

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Cheng, Frank H C ^a   Aguda, Baltazar D ^b   Tsai, Je Chiang ^a   Kochańczyk, Marek ^c   Lin, Jora M J ^a   Chen, Gary C W ^a   Lai, Hung Cheng ^d,e,f,g,h   Nephew, Kenneth P ⁱ   Hwang, Tzy Wei ^a   Chan, Michael W Y ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^b DiseasePathways LLC   (United States)

^c INSTITUTE OF FUNDAMENTAL TECHNOLOGICAL RESEARCH   (Poland)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f CENTRAL SOUTH UNIVERSITY   (China)

^g CENTRAL SOUTH UNIVERSITY   (China)

^h Hunan Key Laboratory of Pharmacogenetics   (China)

ⁱ Indiana University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 193A; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR E2F6; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; E2F6 PROTEIN, HUMAN; MIRN193 MICRORNA, HUMAN;

ARTICLE; CANCER STEM CELL; DOWN REGULATION; EPIGENETICS; GENE SWITCHING; GENETIC REGULATION; MATHEMATICAL MODEL; OVARY CANCER; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UPREGULATION; BIOLOGICAL MODEL; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC DATABASE; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; REPRODUCIBILITY; TUMOR CELL LINE;

BASE SEQUENCE; CELL LINE, TUMOR; DATABASES, GENETIC; E2F6 TRANSCRIPTION FACTOR; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MICRORNAS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; REPRODUCIBILITY OF RESULTS;

EID: 84964693737     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116050     Document Type: Article

References (35)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64: 9-29.
2. Nossov V, Amneus M, Su F, Lang J, Janco JM, et al. (2008) The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 199: 215-223.
3. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, et al. (2007) Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 14: 195-208.
4. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
5. Zhang S, Balch C, Chan MW, Lai HC, Matei D, et al. (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320.
6. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22: 255-288.
7. Cunat S, Hoffmann P, Pujol P (2004) Estrogens and epithelial ovarian cancer. Gynecol Oncol 94: 25-32.
8. Weiss NS, Lyon JL, Krishnamurthy S, Dietert SE, Liff JM, et al. (1982) Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 68: 95-98.
9. Lacey JV Jr, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, et al. (2006) Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 98: 1397-1405.
10. Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, et al. (2004) Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164: 2253-2259.
11. Beral V, Bull D, Green J, Reeves G (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369: 1703-1710.
12. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11: 726-734.
13. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
14. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
15. Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298.
16. Garzon R, Marcucci G, Croce CM (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-789.
17. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, et al. (2008) A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 105: 13556-13561.
18. Gao XN, Lin J, Li YH, Gao L, Wang XR, et al. (2011) MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene 30: 3416-3428.
19. Heller G, Weinzierl M, Noll C, Babinsky V, Ziegler B, et al. (2012) Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res 18: 1619-1629.
20. Li Y, Gao L, Luo X, Wang L, Gao X, et al. (2013) Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood 121: 499-509.
21. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J (2008) Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68: 2094-2105.
22. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, et al. (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38: 1289-1297.
23. Chen HZ, Tsai SY, Leone G (2009) Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 9: 785-797.
24. Trimarchi JM, Fairchild B, Wen J, Lees JA (2001) The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proc Natl Acad Sci U S A 98: 1519-1524.
25. Attwooll C, Oddi S, Cartwright P, Prosperini E, Agger K, et al. (2005) A novel repressive E2F6 complex containing the polycomb group protein, EPC1, that interacts with EZH2 in a proliferationspecific manner. J Biol Chem 280: 1199-1208.
26. Velasco G, Hube F, Rollin J, Neuillet D, Philippe C, et al. (2010) Dnmt3b recruitment through E2F6 transcriptional repressor mediates germ-line gene silencing in murine somatic tissues. Proc Natl Acad Sci U S A 107: 9281-9286.
27. Gerstein MB, Kundaje A, Hariharan M, Landt SG, Yan KK, et al. (2012) Architecture of the human regulatory network derived from ENCODE data. Nature 489: 91-100.
28. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP (2011) A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146: 353-358.
29. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, et al. (2010) A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465: 1033-1038.
30. Makar AP (2000) Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer 7: 85-93.
31. Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, et al. (2007) Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 13: 3617-3622.
32. Network TR (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
33. Li H, Cai Q, Godwin AK, Zhang R (2010) Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res 8: 1610-1618.
34. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, et al. (2010) Regulation of tumor angiogenesis by EZH2. Cancer Cell 18: 185-197.
35. Chau WK, Ip CK, Mak AS, Lai HC, Wong AS (2013) c-Kit mediates chemoresistance and tumorinitiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene 32: 2767-2781.